Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Heron Therapeutics reports strong sales growth and successful product launches

Heron Therapeutics showcased strong sales growth and successful product launches in Q4 2022.
While facing challenges such as delayed EU launch and regulatory concerns, the company is focused on strategic growth opportunities.
Opportunities to increase product uptake and drive market penetration through targeted strategies were discussed.
Overall, Heron Therapeutics remains optimistic about future updates and growth prospects.

Heron Therapeutics reports strong Q1 earnings amidst product challenges

Heron Therapeutics' Q1 2023 performance reflects revenue growth and a strategic focus on key products despite operational challenges.
The company's strengths in product innovation and market potential position it well for future growth opportunities.
Addressing challenges in product uptake and operational efficiency will be crucial for Heron Therapeutics to sustain its positive momentum.
By leveraging opportunities in product expansion and strategic realignment, the company can enhance profitability and drive long-term success.

Heron Therapeutics reports revenue growth and strategic financing for future

Heron Therapeutics delivered solid revenue growth in Q2 2023, driven by strong sales performance in its oncology portfolio and strategic financing activities.
While facing operating losses, the company remains focused on cost-saving initiatives, product growth, and maximizing asset value to drive future profitability.
Opportunities lie in upcoming product expansions, market acceptance of new launches, and strategic partnerships to fuel Heron Therapeutics' growth trajectory.
With a resilient financial position and a clear strategic direction, Heron Therapeutics is poised for future success in the competitive pharmaceutical landscape.

Heron Therapeutics cuts costs, boosts margins, eyes revenue growth

Heron Therapeutics demonstrated strong financial discipline with reduced operational expenses and improving gross margins. Record-high unit sales of key products and a clear commercial strategy position the company for revenue growth. While facing financial challenges and aiming for profitability, Heron Therapeutics remains optimistic about the growth potential of its key products.

Heron Therapeutics exceeds revenue expectations, eyes profitability by Q4 2024

Heron Therapeutics delivered robust financial results in Q4 2023, driven by strong oncology franchise performance and strategic partnerships. With a focus on innovation, cost efficiency, and revenue expansion, the company aims to achieve positive EBITDA by Q4 2024 and capitalize on market opportunities for sustained growth.

Heron Therapeutics excels in Q1, eyes profitability by 2024

Heron Therapeutics made notable progress in Q1 2024, with achievements in product performance, revenue growth, and profitability targets.
While facing challenges in EBITDA variability and regulatory compliance, the company is well-positioned to capitalize on growth opportunities.
By leveraging strengths in sales strategies, R&D focus, and financial efficiency, Heron Therapeutics aims for sustained success in the market.
Overall, the company's strategic initiatives and strong financial outlook signal a positive trajectory for future growth and market expansion.

Heron Therapeutics (HRTX) reports robust Q2 performance and strategic growth plans

Heron Therapeutics (HRTX) delivered strong financial performance with revenue growth, improved margins, and effective expense control in Q2 2024.
Despite challenges like potential competition and regulatory uncertainties, HRTX's strategic strengths in product portfolio and partnerships position it for future success.
Opportunities for growth through product expansions, partnerships, and expense management strategies highlight a positive outlook for HRTX in the competitive market.

Heron Therapeutics excels in Q3 with strong revenue growth and strategic advancements

Heron Therapeutics showcased robust financial performance, strategic partnerships, and product advancements in Q3 2024, positioning the company for sustained growth.
While facing challenges in operational efficiency and regulatory compliance, the company's strengths in innovation and market positioning offer avenues for continued success.
With a focus on expanding market presence, driving product adoption, and navigating regulatory landscapes, Heron Therapeutics is poised for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call Transcript

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 8.47% and 20.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue Estimates

SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise ZYNRELEF:   The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (FDA) in May 2021.

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Cassava Sciences Inc

As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keeping an eye on companies that could be subject to a short squeeze.

Are Herron Therapeutics, Cassava Sciences Ripe for a Short Squeeze?

The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.

Heron's (HRTX) Zynrelef Gets FDA Nod for Label Expansion

The company got approval for an expanded use for its post-surgery pain therapy.

Why Heron Therapeutics Shares Rose Nearly 15% This Week

The stock price of Heron Therapeutics Inc (NASDAQ: HRTX) increased by over 12% during intraday trading today. This is why it happened.

Heron Therapeutics Stock (HRTX): Why The Price Jumped Today

The FDA has approved Heron Therapeutics Inc's (NASDAQ: HRTX) supplemental application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication.  Zynrelef is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

FDA Approves Indication Expansion For Heron Therapeutics' Post-Op Pain Med

Cortexyme Inc

Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.

2 Short-Squeeze Candidates That Could Go Parabolic Soon

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults. HTX-019 is a proprietary intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist (RA) that is approved for PONV prevention.

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA

SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Heron management will present and host one-on-one meetings at the following investor conferences. Jefferies London Healthcare Conference: November 18-19, 2021 Fireside chat will be available on-demand for attendees during the virtual portion of the meeting beginning on Thursday, November 18, 2021.

Heron Therapeutics to Present at Upcoming Investor Conferences

Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 30, 2021 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise ZYNRELEF Now Available: The ZYNRELEF (bupivacaine and meloxicam) extended-release solution New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (FDA) in May 2021.

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Wednesday, November 3, 2021 at 4:15 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.

Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021

bluebird bio

These once-promising biotech stocks are trading at a fraction of their all-time highs right now.

Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?

After setbacks with the FDA, Heron finally launched Zynrelef in July with a constricted label to market. I believe Zynrelef might struggle in its first few quarters on the market. Heron is looking to broaden Zynrelef's label with supplementary studies. In addition, the company has given Zynrelef a competitive price tag to help improve coverage.

Heron Therapeutics: Looking For Signs Of The Bottom

SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced submission of a supplemental New Drug Application (NDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution for an expanded indication.  ZYNRELEF is currently indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting

SAN DIEGO, Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D.

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and six months ended June 30, 2021 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise ZYNRELEF Now Available: In May 2021, the U.S. Food and Drug Administration (FDA) approved the Company's New Drug Application (NDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution.

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled, "Opioid-Free Recovery After Hernia Repair With HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting." In this study, ZYNRELEF, used with scheduled over-the-counter oral analgesics (acetaminophen and ibuprofen) and a personalized opioid prescription algorithm in a real-world environment, enabled more than 90% of patients to be discharged without an opioid prescription, with no callbacks for pain management and 95% of patients to recover opioid-free.

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

Heron Therapeutics Inc (NASDAQ: HRTX) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults aged 65 years and older after bunionectomy and hernia repair. Zynrelef is an extended-release solution of bupivacaine and meloxicam indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia.

News for Heron Therapeutics Stock (HRTX)